ALFA Finder
Fri, 6 Nov
Sai Life Sciences
Q2 revenue up 23% YoY, H1 up 17%, EBITDA margin steady at 28%. Management deflected on H2 figures, capacity timing and revenue visibility.
Summary ready
Earnings calls
Sai Life Sciences concalls
Every Sai Life Sciences earnings call we streamed: the live audio and our summary of what management said.
Calls
Q2 FY27: key takeaways
Call page →Q2 revenue up 23% YoY, H1 up 17%, EBITDA margin steady at 28%. Management deflected on H2 figures, capacity timing and revenue visibility.
Outlook
No numeric guidance; H2 'stronger' than H1, unquantified. FY27 capex ₹1,100–1,300 Cr; ₹621 Cr spent in H1.
Earlier call summaries
All →
14:10 IST
BSE
Earnings Call
Sai Life Science Earnings Call: Key Takeaways
Sai Life Sciences reported robust FY26 performance with 29% revenue growth and 109% PAT growth, driven by deepening engagement with 19 of top 25 global pharma companies.
14:24 IST
BSE
Earnings Call
Sai Life Science Earnings Call: Key Takeaways
Sai Life Sciences delivered strong FY26 performance with 29% revenue growth and 56% EBITDA growth, driven by expansion in CDMO and CRO segments and improved operating leverage.
Sai Life Sciences Ltd: key numbers
- Share price
- ₹1,785.10
- Market cap
- ₹37,928 Cr
- Revenue (annual)
- ₹2,192 Cr
- Net profit (annual)
- ₹348.9 Cr
- P/E (TTM)
- 100.8×Sector 43.0×
- Promoter holding
- 34.50%-0.03% QoQ
- FII holding
- 19.91%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.